|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
Inside Washington: Major Changes Ahead for FDA
Author(s)Jill Wechsler
by Jill Wechsler A new FDA commissioner will have to oversee agency consolidation and new initiatives to counter bioterrorism.
Advertisement
Articles in this issue
almost 23 years ago
Bioinformatics Databases ? Questions of Copyrightalmost 23 years ago
European Editor's Report ? An Industry Comes of Agealmost 23 years ago
Guest Editorial: Back to the Beginningalmost 23 years ago
You Have Failed . . . A Case Study in Warning Letter Remediationalmost 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
